BACKGROUND: Human prion diseases, although variable in clinicopathological phenotype, generally present as neurologic or neuropsychiatric conditions associated with rapid multifocal central nervous system degeneration that is usually dominated by dementia and cerebellar ataxia. Approximately 15% of cases of recognized prion disease are inherited and associated with coding mutations in the gene encoding prion protein (PRNP). The availability of genetic diagnosis has led to a progressive broadening of the recognized spectrum of disease. METHODS: We used longitudinal clinical assessments over a period of 20 years at one hospital combined with genealogical, neuropsychological, neurophysiological, neuroimaging, pathological, molecular genetic, and biochemical studies, as well as studies of animal transmission, to characterize a novel prion disease in a large British kindred. We studied 6 of 11 affected family members in detail, along with autopsy or biopsy samples obtained from 5 family members. RESULTS: We identified a PRNP Y163X truncation mutation and describe a distinct and consistent phenotype of chronic diarrhea with autonomic failure and a length-dependent axonal, predominantly sensory, peripheral polyneuropathy with an onset in early adulthood. Cognitive decline and seizures occurred when the patients were in their 40s or 50s. The deposition of prion protein amyloid was seen throughout peripheral organs, including the bowel and peripheral nerves. Neuropathological examination during end-stage disease showed the deposition of prion protein in the form of frequent cortical amyloid plaques, cerebral amyloid angiopathy, and tauopathy. A unique pattern of abnormal prion protein fragments was seen in brain tissue. Transmission studies in laboratory mice were negative. CONCLUSIONS: Abnormal forms of prion protein that were found in multiple peripheral tissues were associated with diarrhea, autonomic failure, and neuropathy. (Funded by the U.K. Medical Research Council and others.).
BACKGROUND: Human prion diseases, although variable in clinicopathological phenotype, generally present as neurologic or neuropsychiatric conditions associated with rapid multifocal central nervous system degeneration that is usually dominated by dementia and cerebellar ataxia. Approximately 15% of cases of recognized prion disease are inherited and associated with coding mutations in the gene encoding prion protein (PRNP). The availability of genetic diagnosis has led to a progressive broadening of the recognized spectrum of disease. METHODS: We used longitudinal clinical assessments over a period of 20 years at one hospital combined with genealogical, neuropsychological, neurophysiological, neuroimaging, pathological, molecular genetic, and biochemical studies, as well as studies of animal transmission, to characterize a novel prion disease in a large British kindred. We studied 6 of 11 affected family members in detail, along with autopsy or biopsy samples obtained from 5 family members. RESULTS: We identified a PRNP Y163X truncation mutation and describe a distinct and consistent phenotype of chronic diarrhea with autonomic failure and a length-dependent axonal, predominantly sensory, peripheral polyneuropathy with an onset in early adulthood. Cognitive decline and seizures occurred when the patients were in their 40s or 50s. The deposition of prion protein amyloid was seen throughout peripheral organs, including the bowel and peripheral nerves. Neuropathological examination during end-stage disease showed the deposition of prion protein in the form of frequent cortical amyloid plaques, cerebral amyloid angiopathy, and tauopathy. A unique pattern of abnormal prion protein fragments was seen in brain tissue. Transmission studies in laboratory mice were negative. CONCLUSIONS: Abnormal forms of prion protein that were found in multiple peripheral tissues were associated with diarrhea, autonomic failure, and neuropathy. (Funded by the U.K. Medical Research Council and others.).
Authors: S Demart; J G Fournier; C Creminon; Y Frobert; F Lamoury; D Marce; C Lasmézas; D Dormont; J Grassi; J P Deslys Journal: Biochem Biophys Res Commun Date: 1999-11-30 Impact factor: 3.575
Authors: Suman Jayadev; David Nochlin; Parvoneh Poorkaj; Ellen J Steinbart; James A Mastrianni; Thomas J Montine; Bernardino Ghetti; Gerard D Schellenberg; Thomas D Bird; James B Leverenz Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: J D Wadsworth; S Joiner; A F Hill; T A Campbell; M Desbruslais; P J Luthert; J Collinge Journal: Lancet Date: 2001-07-21 Impact factor: 79.321
Authors: Gábor G Kovács; Gianriccardo Trabattoni; Johannes A Hainfellner; James W Ironside; Richard S G Knight; Herbert Budka Journal: J Neurol Date: 2002-11 Impact factor: 4.849
Authors: Andrew F Hill; Susan Joiner; Jonathan D F Wadsworth; Katie C L Sidle; Jeanne E Bell; Herbert Budka; James W Ironside; John Collinge Journal: Brain Date: 2003-06 Impact factor: 13.501
Authors: R Medori; H J Tritschler; A LeBlanc; F Villare; V Manetto; H Y Chen; R Xue; S Leal; P Montagna; P Cortelli Journal: N Engl J Med Date: 1992-02-13 Impact factor: 91.245
Authors: P Cortelli; P Parchi; M Contin; G Pierangeli; P Avoni; P Tinuper; P Montagna; A Baruzzi; P L Gambetti; E Lugaresi Journal: Clin Auton Res Date: 1991-03 Impact factor: 4.435
Authors: Julie Ann Edgeworth; Anita Sicilia; Jackie Linehan; Sebastian Brandner; Graham S Jackson; John Collinge Journal: J Gen Virol Date: 2010-11-17 Impact factor: 3.891
Authors: Mee-Ohk Kim; Leonel T Takada; Katherine Wong; Sven A Forner; Michael D Geschwind Journal: Cold Spring Harb Perspect Biol Date: 2018-05-01 Impact factor: 10.005
Authors: Leonel T Takada; Mee-Ohk Kim; Ross W Cleveland; Katherine Wong; Sven A Forner; Ignacio Illán Gala; Jamie C Fong; Michael D Geschwind Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2017-01 Impact factor: 3.568